Market revenue in 2023 | USD 7,322.3 million |
Market revenue in 2030 | USD 27,165.2 million |
Growth rate | 20.6% (CAGR from 2023 to 2030) |
Largest segment | Surrogate endpoints |
Fastest growing segment | Predictive Biomarkers |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Endpoints |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biomarker clinical phase outsourcing services market will help companies and investors design strategic landscapes.
surrogate endpoints was the largest segment with a revenue share of 55.73% in 2023. Horizon Databook has segmented the Global biomarker clinical phase outsourcing services market based on predictive biomarkers, prognostic biomarkers, safety biomarkers, surrogate endpoints covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of global-level data and insights on the Global biomarker clinical phase outsourcing services market , including forecasts for subscribers. This global databook contains high-level insights into Global biomarker clinical phase outsourcing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account